
"Three" kinds of regalia such as crown, orb, and sward are often necessary to be a high king for conquering the world. For fighting off cancerous diseases, what do we need? This "triple" chemical modified nanomaterial might be save the patient.
Cancer is a leading cause of death worldwide. Under this situation, a successful tumor selective drug targeting and minimized toxicity of cancer drug are urgently necessary.
Scientists from Japan Advanced Institute of Science and Technology (JAIST) and Centre national de la recherche scientifique (CNRS), and their colleagues have developed a type of nanomedicine based on multi-functional graphene that allows for targeted cancer treatment at molecular level.
Single molecular sheet graphene is a promising carbon nanomaterial for various fundamental and practical applications in the next decade because of its excellent physico-chemical features. Graphene has been also known to have a good biocompatibility and biodegradability, thus leading to explore this nanocarbon as drug delivery carrier. However, it is not easy to modify a lot of individual functional molecules onto a graphene nano-sheet at the same time for its biomedical applications.
Developed by Prof. Eijiro Miyako from JAIST (Nomi, Japan), Dr. Alberto Bianco from CNRS (Strasbourg, France), and their international teams, the multi-functional graphene as a drug delivery carrier are successfully synthesized with "three" type of molecules such as near-infrared (NIR) fluorescent probe (indocyanine green; ICG), tumor targeting molecule (Folic acid: FA), and anticancer drug (doxorubicin; Dox) by a covalent chemical modification technique (Figure 1). ICG (green color part in the picture) was chosen as fluorophore to follow the uptake and to track the material inside the cells. FA (blue) was covalently bound through a polyethylene glycol (pink) linked to graphene, to specifically target the cancer cells, and Dox (red) was used as anticancer drug.
Aside from testing the therapeutic abilities to eliminate cancer cells in a culture dish, the team found that the unique properties of this multi-functional graphene showed an enhanced anticancer activity with excellent cancer targeting effect. This would open the doors to future biomedical applications of this type of material. The team plans to continue exploring multi-functional graphene towards the cancer therapy using murine animal model.
Rational chemical multifunctionalization of graphene interface enhances targeting cancer therapy
Matteo Andrea Lucherelli, Yue Yu, Giacomo Reina, Gonzalo Abellán, Eijiro Miyako, Alberto Bianco
Angewandte Chemie International Edition (2020)
DOI: 10.1002/anie.201916112
Contact information:
Eijiro Miyako
JAIST Associate Professor
e-miyako@jaist.ac.jp
Phone: 0761-51-1540
Eijiro Miyako Lab
Japan Advanced Institute of Science and Technology (JAIST)

Mecwins has described its AVAC technology, which labels target proteins with plasmonic nanoparticles and counts each one individually by dark-field micro-spectrophotometry. The AVAC Analyzer reaches femtogram-range sensitivity.
Hesperos has received an SBIR Phase II grant (R44AI197758) from NIAID to expand its Malaria-on-a-Chip platform, adding support for viable, replicating parasite strains and predictive PK/PD modeling.

UCLA researchers have shown that briefly squeezing a cell's nucleus for milliseconds can loosen tightly packed DNA and make CRISPR activation far more effective at reprogramming cell identity. After mapping which genomic regions opened, they aimed guide RNAs at those sites, raising the share of mouse skin cells converted to neurons from about 3% to 10%. Adding a priming step that activated Oct4 pushed conversion to roughly 40%.
This week in nanotech
$108.5M raised
7 funding rounds · 39 deals tracked
New products
Nion-compatible In Situ STEM Holders for Electrical BiasingHummingbird Scientific Featured
Orion Sputtering Deposition SystemsAJA International Featured
Aether®Lam ResearchMarket insights
Last 30 days: Quantum Technologies drew the most money: $3.17B.
Money raised per month
Behind the deal
Who invested in Vertical Semiconductor’s $73M Grant?
See the investors with Insights Pro →